

## 11th International Lung Cancer Congress

Terranea  
Rancho Palos Verdes, CA  
July 8-11, 2010

Agenda Last Updated: September 8, 2010 (be sure to check that this agenda is the latest version)

### Thursday, Jul 8, 2010

6:30 am **Breakfast and Registration**

7:00 am **Welcome and Introductions**

7:05 am **Pre-session Survey**

#### State of the Art: Early-Stage NSCLC Chair: David Gandara

7:15 am **Stage vs. Molecular Markers in Selecting Adjuvant Therapy for Stage IIA NSCLC**  
*Stage: Stephen Swisher*  
*Molecular Markers: Heather Wakelee*

7:45 am **Question-and-Answer Session**

7:50 am **How I Manage: Optimal Management of Patients With Early NSCLC and Compromised Lung Function**  
*Walter Curran, Jr*

8:10 am **Question-and-Answer Session**

8:15 am **When Are Sublobar Resections Appropriate?**  
*Harvey I. Pass*

8:35 am **Question-and-Answer Session**

8:40 am **Restaging After Induction Therapy for Stage III NSCLC**  
*David M. Jablons*

9:00 am **Question-and-Answer Session**

9:05 am **Keynote Lecture: Neoadjuvant and Adjuvant Chemotherapy**  
*Frances Shepherd*

9:35 am **Question-and-Answer Session**

9:40 am **Panel Discussion: Implications of the IASLC Staging Project**  
*Moderators: Harvey I. Pass, Masahiro Tsuboi*

10:10 am **Break**

#### Maintenance and Second-line Therapy in Advanced NSCLC Chair: Roy Herbst

10:25 am **Definition and Goals of Maintenance Therapy**  
*Karen Kelly*

10:45 am **Question-and-Answer Session**

10:50 am **Cytotoxic Agents**  
*Glenwood Goss*

11:10 am **Question-and-Answer Session**

|                   |  |                                   |
|-------------------|--|-----------------------------------|
| 11:15 am          | <b>Targeted Agents</b>   | <i>Thomas Lynch</i>               |
| 11:35 am          | <b>Question-and-Answer Session</b>   |                                   |
| 11:40 am          | <b>Approaches to the Second-line Treatment of Metastatic NSCLC</b>                     | <i>Joan H. Schiller</i>           |
| 12:00 pm          | <b>Postsession Survey</b>  |                                   |
| 12:05 pm          | <b>Case-Based Panel Discussion: Maintenance Therapy</b>                                | <i>Moderator: Karen Kelly</i>     |
| 12:25 pm          | <b>Poster Discussion 1</b>   | <i>Kemp H. Kernstine</i>          |
| 12:45 pm          | <b>Adjourn</b>   |                                   |
| <b>Workshop 1</b> |  |                                   |
| 2:00 pm-4:00 pm   | <b>The Next Generation of Targeted Agents in Lung Cancer (CME-Designated Workshop)</b> | <i>Chair: Michael S. O'Reilly</i> |
| 2:00 pm           | <b>ALK Inhibitors</b>  | <i>Tianhong Li</i>                |
| 2:15 pm           | <b>Question-and-Answer Session</b>   |                                   |
| 2:20 pm           | <b>Targeting PI3K/Akt</b>  | <i>Alex A. Adjei</i>              |
| 2:35 pm           | <b>Question-and-Answer Session</b>   |                                   |
| 2:40 pm           | <b>PARP Inhibitors</b>   | <i>David Gandara</i>              |
| 2:55 pm           | <b>Question-and-Answer Session</b>   |                                   |
| 3:00 pm           | <b>MEK Inhibitors</b>  | <i>Michael S. O'Reilly</i>        |
| 3:15 pm           | <b>Question-and-Answer Session</b>   |                                   |
| 3:20 pm           | <b>VEGFR TKIs: Where Do We Go From Here?</b>   | <i>Alex A. Adjei</i>              |
| 3:35 pm           | <b>Question-and-Answer Session</b>   |                                   |
| 3:40 pm           | <b>c-Met Inhibitors</b>  | <i>Primo N. Lara, Jr</i>          |
| 3:55 pm           | <b>Question-and-Answer Session</b>   |                                   |
| 4:00 pm           | <b>Overcoming T790M Mutations</b>  | <i>Karen Kelly</i>                |
| 4:15 pm           | <b>Question-and-Answer Session</b>   |                                   |
| 4:20 pm           | <b>Adjourn</b>   |                                   |
| 6:30 pm-7:30 pm   | <b>Welcome Reception</b>   | <i>(Palos Verdes Terrace)</i>     |

## Friday, Jul 9, 2010

|         |                                     |                            |
|---------|-------------------------------------|----------------------------|
| 6:20 am | <b>Breakfast and Registration</b>   |                            |
| 7:00 am | <b>Welcome and Introductions</b>    |                            |
| 7:05 am | <b>Presession Survey</b>            |                            |
| 7:10 am | <b>Tumor Board (Advanced NSCLC)</b> | <i>Chair: Corey Langer</i> |

**Third Annual Addario Foundation Keynote Lecture**  
**Chair: Roy Herbst**

|   |  |   |
|---|--|---|
| 8:10 am   | <b>Linking Molecular Epidemiology to Therapeutic Strategies in NSCLC</b> | <i>David Gandara</i>  |
| 8:35 am   | <b>Question-and-Answer Session</b>                                       |   |
| 8:40 am   | <b>Break</b>   |   |
| <b>Personalized Medicine for NSCLC</b><br>Chair: <b>Giorgio Scagliotti</b>    |  |   |
| 8:55 am   | <b>Overview of Personalized Medicine</b>                                 | <i>Paul A. Bunn, Jr</i>   |
| 9:15 am   | <b>Question-and-Answer Session</b>                                       |   |
| 9:20 am   | <b>Biomarkers for Personalized Lung Cancer Therapy</b>                   | <i>Giorgio Scagliotti</i>                                       |
| 9:40 am   | <b>Question-and-Answer Session</b>                                       |   |
| 9:45 am   | <b>Gene Signatures vs. Individual Markers</b>                            | <i>Fred Hirsch</i>  |
| 10:05 am  | <b>Question-and-Answer Session</b>                                       |   |
| 10:10 am  | <b>Special Populations (Women, Elderly, PS2)</b>                         | <i>Joan H. Schiller</i>   |
| 10:30 am  | <b>Question-and-Answer Session</b>                                       |   |
| 10:35 am  | <b>Case-Based Panel Discussion: Personalized Medicine</b>                | <i>Moderator: Paul A. Bunn, Jr</i>                              |
| 10:55 am  | <b>Break</b>   |   |
| <b>Personalized Medicine for Mesothelioma</b><br>Chair: <b>Harvey I. Pass</b> |  |   |
| 11:10 am  | <b>Locally Advanced Disease</b>  | <i>Kemp H. Kernstine</i>  |
| 11:30 am  | <b>Question-and-Answer Session</b>                                       |   |
| 11:35 am  | <b>Advanced Disease</b>  | <i>Paul Baas</i>  |
| 11:55 am  | <b>Question-and-Answer Session</b>                                       |   |
| 12:00 pm  | <b>Postsession Survey</b>  |   |
| 12:05 pm  | <b>Panel Discussion</b>  | <i>Moderator: Paul Baas</i>                                     |
| 12:25 pm  | <b>Poster Discussion 2</b>   | <i>Tianhong Li</i>  |
| 12:45 pm  | <b>Adjourn</b>   |   |
| <b>Workshop 2</b>   |  |   |
| 2:00 pm-4:00 pm   | <b>Multidisciplinary Tumor Board (CME-Designated Workshop)</b>           | <i>Chairs: Stephen Swisher, Hak Choy</i>                        |
|   | <b>Combined Modality Treatment Planning in Early NSCLC</b>               | <i>A. William Blackstock, David M. Jablons</i>                  |
|   | <b>Early Stage With Poor Pulmonary Function</b>                          | <i>A. William Blackstock, Laurie E. Gaspar, Stephen Swisher</i> |
|   | <b>PCI for Stage III NSCLC</b>   | <i>Laurie E. Gaspar; Primo N. Lara, Jr</i>                      |
|   | <b>Submitted Cases</b>   | <i>Hak Choy</i>   |

Saturday, Jul 10, 2010

---

|   |  |  |
|---|--|--|
| 6:20 am   | <b>Breakfast and Registration</b>  |  |
| 7:00 am   | <b>Welcome and Introductions</b>   |  |
| 7:05 am   | <b>Pre-session Survey</b>  |  |
| <b>State-of-the Art in Combined Modality Therapy for Lung Cancer</b><br><b>Chair: Primo N. Lara, Jr</b> |  |  |
| 7:10 am   | <b>State-of-the Art: Combined Modality Therapy</b>   | <i>Everett E. Vokes</i>                                  |
| 7:30 am   | <b>Question-and-Answer Session</b>   |  |
| 7:35 am   | <b>Optimal Radiation Dose and Schedule for Chemoradiation Therapy in Stage III NSCLC</b>         | <i>A. William Blackstock</i>                             |
| 7:55 am   | <b>Question-and-Answer Session</b>   |  |
| 8:00 am   | <b>Introducing Targeted Agents Into Combined Modality Therapy for NSCLC</b>                      | <i>Primo N. Lara, Jr</i>                                 |
| 8:20 am   | <b>Question-and-Answer Session</b>   |  |
| 8:25 am   | <b>Surgical Approaches to Locally Advanced NSCLC</b>   | <i>Harvey I. Pass</i>                                    |
| 8:45 am   | <b>Question-and-Answer Session</b>   |  |
| 8:50 am   | <b>Innovative Approaches to Radiation Therapy, Including SBRT, IMRT, and Proton Beam Therapy</b> | <i>Hak Choy</i>  |
| 9:10 am   | <b>Question-and-Answer Session</b>   |  |
| 9:15 am   | <b>Current Approaches to the Treatment of LD-SCLC</b>  | <i>Laurie E. Gaspar</i>                                  |
| 9:35 am   | <b>Question-and-Answer Session</b>   |  |
| 9:40 am   | <b>Case-Based Panel Discussion</b>   | <i>Moderators: Laurie E. Gaspar, Michael S. O'Reilly</i> |
| 10:00 am  | <b>Break</b>   |  |
| <b>State-of-the-Art Treatment of Advanced Lung Cancer (Part 1)</b><br><b>Chair: Roy Herbst</b>          |  |  |
| 10:15 am  | <b>State-of-the Art: Advanced Lung Cancer</b>  | <i>Roy Herbst</i>  |
| 10:35 am  | <b>Question-and-Answer Session</b>   |  |
| 10:40 am  | <b>Treatment of ED-SCLC</b>  | <i>Alan Sandler</i>                                      |
| 11:00 am  | <b>Question-and-Answer Session</b>   |  |
| 11:05 am  | <b>Optimal Application of Antifolates in NSCLC</b>   | <i>Giorgio Scagliotti</i>                                |
| 11:25 am  | <b>Question-and-Answer Session</b>   |  |
| 11:30 am  | <b>Lung Cancer Vaccines</b>  | <i>David M. Jablons</i>                                  |
| 11:50 am  | <b>Question-and-Answer Session</b>   |  |
| 11:55 am  | <b>Post-session Survey</b>   |  |
| 12:00 pm  | <b>Case-Based Panel Discussion</b>   | <i>Moderator: Alan Sandler</i>                           |

|                 |                          |                        |
|-----------------|--------------------------|------------------------|
| 12:20 pm        | <b>Adjourn</b>           |                        |
| 6:00 pm-7:00 pm | <b>Closing Reception</b> | <i>(Point Terrace)</i> |

## Sunday, Jul 11, 2010

---

|  |  |  |
|--|--|--|
| 6:20 am  | <b>Breakfast</b>   |  |
| 7:00 am  | <b>Welcome and Introductions</b>                                     |  |
| <b>State-of-the-Art Treatment of Advanced Lung Cancer (Part 2)</b><br>Chair: Alex A. Adjei |  |  |
| 7:05 am  | <b>Novel Cytotoxics in Metastatic NSCLC</b>                          | <i>Corey Langer</i>                      |
| 7:25 am  | <b>Question-and-Answer Session</b>                                   |  |
| 7:30 am  | <b>IGF-1R Inhibitors</b>   | <i>Alex A. Adjei</i>                     |
| 7:50 am  | <b>Question-and-Answer Session</b>                                   |  |
| 7:55 am  | <b>Frontline Management of Advanced NSCLC in East Asian Patients</b> | <i>Masahiro Tsuboi</i>                   |
| 8:15 am  | <b>Question-and-Answer Session</b>                                   |  |
| 8:20 am  | <b>Break</b>   |  |
| <b>Cooperative Group Update</b><br>Moderator: Claudio Dansky Ullmann                       |  |  |
| 8:35 am  | <b>Overview</b>  | <i>Claudio Dansky Ullmann</i>            |
| 8:55 am  | <b>Japan</b>   | <i>Nagahiro Saijo</i>                    |
| 9:15 am  | <b>Europe</b>  | <i>Paul Baas</i>                         |
| 9:35 am  | <b>SWOG</b>  | <i>David Gandara</i>                     |
| 9:55 am  | <b>RTOG</b>  | <i>Jeffrey D. Bradley</i>                |
| 10:15 am   | <b>NCI-Canada</b>  | <i>Glenwood Goss</i>                     |
| 10:35 am   | <b>NCCTG</b>   | <i>Alex A. Adjei</i>                     |
| 10:55 am   | <b>ECOG</b>  | <i>Corey Langer</i>                      |
| 11:15 am   | <b>CALGB</b>   | <i>Everett E. Vokes</i>                  |
| 11:35 am   | <b>ACOSOG</b>  | <i>Kemp H. Kernstine</i>                 |
| 11:55 am   | <b>Panel Discussion/Question-and-Answer Session</b>                  | <i>Moderator: Claudio Dansky Ullmann</i> |
| 12:10 pm   | <b>Closing Remarks</b>   |  |
| 12:15 pm   | <b>Adjourn</b>   |  |